WallStSmart
NEUP

Neuphoria Therapeutics Inc

NASDAQ: NEUP · HEALTHCARE · BIOTECHNOLOGY

$3.36
-0.88% today

Updated 2026-10-28

Market cap
$18.61M
P/E ratio
—
P/S ratio
15.85x
EPS (TTM)
$-3.06
Dividend yield
—
52W range
$3 – $6
Volume
0.0M

Neuphoria Therapeutics Inc (NEUP) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-1,145.66%
Operating margin
-835.53%
ROE
-93.64%
ROA
-19.70%
Debt/equity
0.00x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2007$693210.00$-4.62M100.00%-1,241.06%-666.81%
2008$1.08M$-4.58M100.00%-661.69%-424.86%
2009$2.91M$-5.54M100.00%-293.41%-190.07%
2010$2.54M$-6.98M100.00%-291.29%-274.41%
2011$3.40M$-10.00M100.00%-308.11%-293.94%
2012$5.35M$-3.21M21.56%-228.45%-60.04%
2013$2.50M$-9.13M59.83%-731.48%-365.50%
2014$18.02M$3.02M51.03%-19.77%16.75%
2015$5.08M$-13.00M-160.24%-397.51%-255.68%
2016$5.21M$-12.40M100.00%-415.73%-237.84%
2017$27.15M$-5.19M10.44%-51.00%-19.11%
2018$11.94M$-18.43M-112.49%-178.18%-154.30%
2019$7.40M$-6.77M36.22%-145.46%-91.57%
2020$32062.00$-4.89M100.00%-19,319.28%-15,255.18%
2021$927544.00$-6.53M-136.74%-965.74%-704.48%
2022$383156.00$-22.94M-2,604.39%-8,095.19%-5,986.91%
2023$0.00$-32.18M———
2024$0.00$-15.49M———
2025$15.65M$-369632.0095.76%-7.21%-2.36%
2026$1.17M$-13.45M43.54%-835.53%-1,145.66%

Frequently asked questions

What is Neuphoria Therapeutics Inc's revenue?

Neuphoria Therapeutics Inc's trailing twelve-month revenue is $1.17M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is NEUP?

In its most recent fiscal year, NEUP ran a gross margin of 43.54%, an operating margin of -835.53%, and a net margin of -1,145.66%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does NEUP generate?

NEUP produced $-12.35B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NEUP's balance sheet healthy?

NEUP holds $19.87B in cash and equivalents against — in long-term debt, on $24.60B of shareholder equity. That debt is best read against the cash flow the business throws off each year.